воскресенье, 26 июня 2016 г.

Can Gilead Sciences Rebound in the Second Half of 2016?

Can Gilead Sciences Rebound in the Second Half of 2016?


What: Shares of the blue-chip biotech Gilead Sciences have now fallen by close to 20% in 2016, according to data from S&P Global Market Intelligence . Gilead's hefty decline was triggered by weaker-than-expected sales of its megablockbuster hepatitis C drug Harvoni in the first quarter of the year, combined with the approval and subsequent launch of Merck 's competing therapy, Zepatier.



from Biotech News